IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 6369 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  NAVIGATE Here 
    Next article
    Previous article
    Table of Contents

 RESOURCE Links
    Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed7428    
    Printed332    
    Emailed15    
    PDF Downloaded4    
    Comments [Add]    
    Cited by others 1    

Recommend this journal

 

 ORIGINAL ARTICLE
Year : 2002  |  Volume : 68  |  Issue : 2  |  Page : 73--76

Evaluation of the efficacy and safety of fexofenadine in the management of chronic idiopathic urticaria: A prospective study with 512 patients


Divisions of Dermatology and Cardiology, AMRI Goenka Hospital and Duncan Gleneagles Clinic, Calcutta, India

Correspondence Address:
Sandipan Dhar
H.No.6, S.P D. Block Baghajatin, Calcutta - 700 086
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 17656881

Rights and PermissionsRights and Permissions

Five hundred and twelve patients with chronic idiopathic urticaria (CIU) were treated with fexofenadine at a dose on 180mg/day. Maximum number of patients were between 20 to 40 years of age and female to male ratio was 1.45:1. The severity of itching was calculated on a scale of 0 to 4 and was recorded by the patients. The mean daily total symptom score (TSS) was measured as sum of the patients' pruritus and number of wheal scores (0 to 7). A mean TSS was determined for each week. Baseline TSS came down to '0' by 4 weeks in all groups except those with TSS 4. There was no correlation between the baseline TSS and degree of improvement. Of 512, 14 (2.73%) patients did not complete the study. The commonest adverse effect was headache (9.04%). There was no report of drowsiness or cardiac arrythmia. In no patient fexofenadine had to be withdrawn because of its adverse effects.






[FULL TEXT] [PDF Not available]*


        
Print this article     Email this article

Online since 15th March '04
Published by Wolters Kluwer - Medknow